Abstract：Objective Based on the investigation of the current situation and trend of the use of Neuroprotective Agents in six cities in China, to preliminarily evaluate the rationality of the use of Neuroprotective Agents, in order to provide the basic reference data for promoting the rational use of drugs. Methods The data were from sampling prescription of 84 samples of medical and health institutions at all levels in 6 cities (Beijing, Tianjin, Shanghai, Guangzhou, Hangzhou, Chengdu) in China collected in“The Hospital Prescriptions Cooperation Project” of Hospital Pharmacy Committee of Chinese Pharmaceutical Association from January 2012 to December 2016, and the patient′s medication situation was analyzed. Results During the five years, the sales amount of Neuroprotective Agents in six cities increased year by year. The ratio of men to women was about 5 to 4, with the patients aged between 1 and 118 years old, mainly in the 50 to 90 years old, accounting for 75.00%. The distribution of drug departments were mainly in neurology (24.92%), neurosurgery (11.17%), old cadre department (8.47%), emergency department (7.62%) and cardiology (5.33%).The original diagnosis accounted for the top five: cerebral infarction (3.17%), cerebral hemorrhage (1.45%), cerebrovascular disease (0.91%), head trauma (0.50%) and cerebral infarction sequel (0.41%). The amount and kind of drug sales in 2016, Neurotrophic Co-Stimulating (5.2 million yuan) > Membrane Stabilizer (5.1 million yuan) > Calcium Antagonists (2.8 million yuan) > Glutamate Release Inhibitors (2.6 million yuan). The top 5 drug consumption figures were respectively Ganglioside (3.9 million yuan), Mouse Nerve Growth Factor (3.3 million yuan), Butyl Phthalide (2.6 million yuan), Edaravone (2.2 million yuan), Cinepazide (2 million yuan). There was a wide variation in drug use among cities, and each region had its own tendency to use drugs. Conclusion In general, there are clinical abuses in the application of Neuroprotective Agents in six cities in China, which should be used rationally and economically on the basis of ensuring the efficacy and safety of drugs.
王慧媛 杨莉 赵志刚. 2012～2016年我国六城市神经保护剂用药现状调查[J]. 中国医药导报, 2018, 15(3): 46-51.
WANG Huiyuan YANG Li ZHAO Zhigang. Investigation of the current situation of Neuroprotective Agents in six cities in China from 2012 to 2016. 中国医药导报, 2018, 15(3): 46-51.
[1] Troy M，Sepideh AH. Neuroprotectant drug shows promise in human ischemic stroke [J]. World Neurosurg，2013，79（3）：408-411.
[2] Antonino T，Rosaria P，Valentina A，et al. Developing drug strategies for the neuroprotective treatment of acute ischemic stroke [J]. Expert Rev Neurother，2015，15（11）：1271-1284.
[3] 中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2014[J].中华神经科杂志，2015，48（4）：246-257.
[4] 陈新谦，金有豫，汤光.新编药物学[M].17版.北京：人民卫生出社，201l.
[5] 王强，金岩，李婉.药品的解剖学治疗学化学分类索引及规定日剂量[M].北京：中国协和医科大学出版社，2003.
[6] 国家药典委员会.中华人民共和国药典临床用药须知：2010年版，化学药和生物制品卷[M].北京：中国医药科技出版社，2011.
[7] Jauch EC，Saver JL，Adams HP，et al. Guidelines for the early management of patients with acute ischemic stroke-a guideline for healthcare professionals from the American Heart Association/American Stroke Association [J]. Stroke，2013，44（3）：870-947.
[8] Venketasubramanian N，Pwee KH，Chen CP. Singapore ministry of health clinical practice guidelines on stroke and transient ischemic attacks [J]. Int J Stroke，2011，6（3）：251–258.
[9] Bryer A，Connor MD，Haug P，et al. South African guideline for management of ischaemic stroke and transient ischaemic attack [J]. S Afr Med J，2010，100（11）：750-778.
[10] Foundation NS. Clinical guidelines for stroke management 2010 [J]. Stroke，2010，9（1）：1-167.
[11] Committee ESOE，Committee EW. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008 [J]. Cerebrovasc Dis，2008，25（5）：457-507.
[12] 徐安定.解读《欧洲卒中组织2008缺血性卒中/短暂性脑缺血发作指南》[J].中国神经精神疾病杂志，2008，34（10）：577-580.
[13] National Collaborating Centre for Chronic Conditions （UK）. Stroke：national clinical guideline for diagnosis and initial management of acute stroke and transient ischaemic attack （TIA） [J]. Royal College of Physicians，2008.
[14] Party I. National clinical guideline for stroke [J]. Stroke，2012，9（4）：1-209.
[15] Oliveira FJ，Martins SC，Pontes OM. Guidelines for acute ischemic stroke treatment-Part Ⅱ：stroke treatment [J]. Arq Neuropsiquiatr，2012，70（11）：885-893.
[16] Patrice RN，Mark B，Alison MD，et al. Toward a more effective approach to stroke：Canadian best practice recommendations for stroke care [J]. CAMJ，2008，178（11）：1418-1425.
[17] Casaubon LK，Boulanger JM，Blacquiere D，et al. Canadian stroke best practice recommendations：hyperacute stroke care guidelines 2015 [J]. Stroke，2015，10（8），924-950.
[18] Minematsu K，Toyoda K，Hirano T，et al. Guidelines for the intravenous application of recombinant tissue-type plasminogen activator（alteplase），the second edition，October 2012：a guideline from the Japan Stroke Society [J]. J Stroke Cerebrovasc Dis，2013，22（5）：571-600.
[19] Keun HJ，Kyung HY，Young DK，et al. Antithrombotic Management of atients with nonvalvular atrial fibrillation and ischemic stroke or transient ischemic attack：executive summary of the Korean clinical practice guidelines for stroke [J]. Stroke，2015，17（2）：210-215.
2018, Vol. 15 
京公网安备 11010502046598号